Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Urology|March 28, 2023
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer PatientsKelsey E Breen, Heather Symecko, Kelsey Spielman, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Investigational New Drugs|September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
The Lancet. Oncology|September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trialAung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical FactorsKonrad H Stopsack, Subhiksha Nandakumar, Kanika Arora, et al.
JCO Precision Oncology|March 18, 2026
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate CancerJeffery C W Chang, Subhiksha Nandakumar, Konrad H Stopsack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid TumorsAung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Cancer Cell|November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsAung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
Pageof 5